@article{b54409bd5a964197946ad5d485217080,
title = "New Technologies for Outcome Measures in Retinal Disease: Review from the European Vision Institute Special Interest Focus Group",
abstract = "Novel diagnostic tools to measure retinal function and structure are rapidly being developed and introduced into clinical use. Opportunities exist to use these informative and robust measures as endpoints for clinical trials to determine efficacy and to monitor safety of therapeutic interventions. In order to inform researchers and clinician-scientists about these new diagnostic tools, a workshop was organized by the European Vision Institute. Invited speakers highlighted the recent advances in state-of-the-art technologies for outcome measures in the field of retina. This review highlights the workshop's presentations in the context of published literature.",
keywords = "Artificial intelligence, Diagnostics, Machine learning, Retina, Retinal disease, Technologies",
author = "{Della Volpe-Waizel}, Maria and Traber, {Ghislaine L.} and Peter Maloca and Martin Zinkernagel and Ursula Schmidt-Erfurth and Gary Rubin and Botond Roska and Tilman Otto and Weleber, {Richard G.} and Scholl, {Hendrik P.N.}",
note = "Funding Information: P. Maloca is owner of intellectual property on speckle noise analysis and the MIMO-OCT discussed in this article and received lecture fees from Heidelberg Engineering{\textregistered} GmbH and Zeiss. M. Zinkernagel is consultant for Bayer, Novartis, and Allergan and has received grants from Bayer and Boehringer Ingelheim. U. Schmidt-Erfurth declares to be a consultant for Novartis, Genentech, Boehringer, and Roche. T. Otto declares to be the head of research and development at Heidelberg Engineering{\textregistered} GmbH. G. Rubin declares that he is a consultant for Pixium Vision SA and MeiraGTxz. R.G. Weleber declares financial support from the Foundation Fighting Blindness: Vice-Chair for Scientific Advisory Board (SAB), Member of Executive Scientific Advisory Board (ESAB) (honorarium received); AGTC: SAB, Co-Investigator for three trials: RPE65 LCA, XLRS1, CNGB3 ACHR; Consultant (Past): Oxford-Biomedica, Pfizer, Novartis; Consultant (Current): NightStaRx, QLT, 4D Molecular Therapeutics; Sanofi: Past P.I. and now Co-Investigator for two clinical treatment trials: USHSTAT, STARGEN; Holder of US Patent No. 8,657,446 Visual Field Modeling and Analysis (VFMA). A subset of his presentation material was given at a NEI/FDA Endpoints Workshop on Age-Related Macular Degeneration and Inherited Retinal Disease held at the NEI in November 2016 [63]. H.P.N. Scholl declares financial support from the following sources: Data Monitoring Committee: Genentech Inc./F. Hoffmann-La Roche Ltd (CHROMA and SPECTRI trials); Genzyme Corp./Sanofi, and Re-Neuron Group Plc/Ora Inc., Steering Committee: Novo Nordisk (FOCUS trial), Scientific Advisory Board: Astellas Institute for Regenerative Medicine; Gensight Biologics; Intellia Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.; ReNeuron Group Plc/Ora Inc.; Pharma Research and Early Development (pRED) of F. Hoffmann-La Roche Ltd; and Vision Medicines, Inc, Consultancy: Boehringer Ingelheim Pharma GmbH & Co. KG; Daiichi Sankyo, Inc.; Gerson Lehrman Group; Guidepoint; and Shire, Co-director of the Institute of Molecular and Clinical Ophthalmology Basel (IOB), which is constituted as a non-profit foundation and receives funding from the University of Basel, the University Hospital Basel, Novartis, and the government of Basel-Stadt. M. della Volpe-Waizel received consultation fees from Novartis. Except as noted above, all authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers{\textquoteright} bureaus; membership, employment, consultancies, stock ownership, or other equity interest; nor with any expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this article. Funding Information: H.P.N. Scholl was supported by the Swiss National Science Foundation, National Center of Competence in Research Molecular Systems Engineering, the Wellcome Trust, and the Foundation Fighting Blindness Clinical Research Institute and unrestricted grants from Acucela Inc., Aegerion Pharmaceuticals (Novelion Therapeutics), Kinarus AG; NightstaRx Ltd., Ophthotech Corporation and Spark Therapeutics England, Ltd. M. della Volpe- Waizel was supported by unrestricted grant from SAMW (Schweizerische Akademie der Medizinischen Wissenschaften), SNF (Swiss National Science Foundation), and the Bangerter Foundation Publisher Copyright: {\textcopyright} 2019 S. Karger AG, Basel. Copyright: All rights reserved.",
year = "2020",
month = mar,
day = "1",
doi = "10.1159/000501887",
language = "English (US)",
volume = "63",
pages = "77--87",
journal = "Ophthalmic Research",
issn = "0030-3747",
publisher = "S. Karger AG",
number = "2",
}